

Multiple Sclerosis (MS)

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Trial Status
Recruiting

Trial Runs In
2 Countries

Trial Identifier
NCT06675955 2023-507633-21-01
MN45053

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT06675955 2023-507633-21-01 MN45053
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
